Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005659700
Fri, 25.11.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 25 November 2022. PENTIXAPHARM GmbH, a 100% subsidiary of Eckert & Ziegler AG (ISIN DE0005659700, SDAX), received green light from the European Medicines Agency (EMA) to conduct a phase III registration study in patients suffering from various forms of Non-Hodgkin-Lymphomas. Following several rounds of scientific advice, the EMA Committ [ … ]
Fri, 25.11.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 25 November 2022. PENTIXAPHARM GmbH, a 100% subsidiary of Eckert & Ziegler AG (ISIN DE0005659700, SDAX), received green light from the European Medicines Agency (EMA) to conduct a phase III registration study in patients suffering from various forms of Non-Hodgkin-Lymphomas. Following several rounds of scientific advice, the EMA Committ [ … ]
Tue, 08.11.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 8 November 2022. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) increased sales by 25% to EUR 164.0 million in the first nine months of 2022. Net income of EUR 23.3 million was EUR 5.8 million lower than in the same period of the previous year, in which the sale and associated deconsolidation of the tumor irr [ … ]
Tue, 08.11.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 8 November 2022. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) increased sales by 25% to EUR 164.0 million in the first nine months of 2022. Net income of EUR 23.3 million was EUR 5.8 million lower than in the same period of the previous year, in which the sale and associated deconsolidation of the tumor irr [ … ]
Thu, 27.10.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin/Aalborg, 27 October 2022. The University Hospital Aalborg (Denmark) yesterday has imaged the first patient with Eckert and Ziegler’s Gallium (68Ga) boclatixafortide (PENTIXAFOR) in an international phase 2 trial. Code named PTF202, the clinical examination tries to measure the predictive potential of the CXCR4 receptor targeting radiotracer [ … ]
Thu, 27.10.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin/Aalborg, 27 October 2022. The University Hospital Aalborg (Denmark) yesterday has imaged the first patient with Eckert and Ziegler’s Gallium (68Ga) boclatixafortide (PENTIXAFOR) in an international phase 2 trial. Code named PTF202, the clinical examination tries to measure the predictive potential of the CXCR4 receptor targeting radiotracer [ … ]
Thu, 13.10.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 13 October 2022. Eckert & Ziegler (ISIN DE0005659700, SDAX) and Alpha-9 Theranostics Inc. (Alpha-9), a radiopharmaceutical company with offices in Vancouver and Boston, have signed an agreement for the preferred supply of GMP grade Actinium-225. The reservation gives Alpha-9 priority access to Eckert & Ziegler's high-purity, non-car [ … ]
Thu, 13.10.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 13 October 2022. Eckert & Ziegler (ISIN DE0005659700, SDAX) and Alpha-9 Theranostics Inc. (Alpha-9), a radiopharmaceutical company with offices in Vancouver and Boston, have signed an agreement for the preferred supply of GMP grade Actinium-225. The reservation gives Alpha-9 priority access to Eckert & Ziegler's high-purity, non-car [ … ]
Tue, 11.10.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, Germany and BELOIT, Wis., 11 October 2022 - Eckert & Ziegler Isotope Technologies Dresden (ITD), a specialist for radiopharmaceutical plant engineering and fully owned subsidiary of Eckert & Ziegler AG (ISIN DE0005659700, SDAX) and NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercial [ … ]
Tue, 11.10.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, Germany and BELOIT, Wis., 11 October 2022 - Eckert & Ziegler Isotope Technologies Dresden (ITD), a specialist for radiopharmaceutical plant engineering and fully owned subsidiary of Eckert & Ziegler AG (ISIN DE0005659700, SDAX) and NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercial [ … ]